Contact:China Biologic Products, Inc.
Mr. Ming Yin
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEFor the three months ended For the six months ended June 30, June 30, June 30, June 30, 2013201220132012Sales$
97,693,800Cost of sales16,122,26216,130,88932,739,02031,846,616Gross profit 37,458,26134,335,45074,873,23565,847,184Operating expenses
Selling expenses2,441,7274,165,2424,278,1208,991,349General and administrative expenses 8,866,0717,932,37217,553,16815,078,166Research and development expenses 835,150929,4891,748,2421,640,077Income from operations 25,315,31321,308,34751,293,70540,137,592Other income /(expenses)Equity in income of an equity method investee 610,997451,891739,9451,474,303Change in fair value of derivative liabilities -559,758-1,769,140Interest expense
SOURCE China Biologic Products, Inc.
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. BD and the College of American Pathologists Announce Strategic Alliance to Support Laboratory Quality and Performance in India and China
2. China Biologic Products to Report Second Quarter 2013 Financial Results
3. MEDTEC China 2013: Floor space sold out!
4. China Heart Valve Market and Heart Lung Machine Industry Global Analysis in New Research Reports
5. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
6. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
7. China Pharmaceutical Guidebook: Latest Chinese Regulations for Imported Drug Registration
8. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
9. Research Report on Chinas High-End Medical Treatment Industry, 2013-2017
10. China Biologic Waived Application of Preferred Shares Rights Agreement
11. China Botanic Pharmaceutical Inc. Announces Withdrawal Of Request For Hearing